E. Roudasev is a senior business manager for a major financial institution. Her areas of interest are biotech, environmental tech and credit risks. The opportunities in under the radar biotechs, ...

PDS Biotech is a late-stage immunotherapy company preparing to initiate a Phase 3 clinical trial evaluating Versamune HPV + pembrolizumab as a potential first-line treatment for recurrent or ...

WOODLAND HILLS, CA / ACCESSWIRE / August 12, 2024 / BioTech Medics, Inc. (OTC PINK:BMCS) is pleased to announce that the company's CEO sat down for an interview with The Beast of Wall Street on August ...

NEW YORK, NY / ACCESSWIRE / December 5, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently ...

New Taipei City, Taiwan, May 29, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and ...

All industries, including biotechnology, are faced with a drastically different economic environment from that of four or five years ago. To get a sense of how a key biotech supplier that operates on ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Adam Feuerstein is a senior writer and ...

For a biotech executive hoping to make something vast, Chris Gibson seems proudest in obsessing over the tiniest details. Gibson is the CEO of Recursion Pharmaceuticals, a biotech upstart aiming to ...

Lux Capital is advising its biotech startups to focus on three qualities as the public-market pullback threatens to hit private companies. After record years for launching startups, raising capital, ...

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, ...